- Home
- PSNL vs DRUG Comparison
PSNL vs DRUG Comparison
Compare PSNL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | DRUG |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 707.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSNL | DRUG |
|---|---|---|
| Price | $6.29 | $88.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $12.20 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 1.5M | 149.8K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $15.34 | N/A |
| Revenue Next Year | $41.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.63 | $23.18 |
| 52 Week High | $11.50 | $123.75 |
Technical Indicators
Market Signals| Indicator | PSNL | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 63.96 |
| Support Level | $5.81 | $69.83 |
| Resistance Level | $6.94 | $91.00 |
| Average True Range (ATR) | 0.43 | 4.54 |
| MACD | 0.06 | 1.12 |
| Stochastic Oscillator | 41.87 | 89.98 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.